Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Published by Global Banking & Finance Review®
Posted on February 24, 2025
1 min readLast updated: January 25, 2026
Published by Global Banking & Finance Review®
Posted on February 24, 2025
1 min readLast updated: January 25, 2026
Drug compounders sue the FDA for removing Wegovy and Ozempic from the shortage list, affecting cheaper drug sales.
(Reuters) - Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.
(Reporting By Brendan Pierson in New York; Editing by Leslie Adler)
The lawsuit involves Novo Nordisk's weight loss and diabetes drugs, Wegovy and Ozempic.
They sued the FDA over its decision to remove Wegovy and Ozempic from its shortage list.
The article was reported by Brendan Pierson in New York, with editing by Leslie Adler.
Explore more articles in the Headlines category


